Casi pharmaceuticals statement on status under holding foreign companies accountable act

Rockville, md. and beijing , april 1, 2022 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a u.s. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced today that on march 30, 2022, the securities and exchange commission (sec) provisionally identified casi pharmaceuticals inc (casi) on the list, pursuant to the holding foreign companies accountable act (hfcaa), that uses an auditor not subject to public company accounting oversight board (pcaob) inspection.
CASI Ratings Summary
CASI Quant Ranking